Novavax beat Wall Street expectations for second-quarter revenue on Wednesday, helped by a $175 million milestone payment ...

Q2 2025 Earnings Call Transcript August 6, 2025 Novavax, Inc. beats earnings expectations. Reported EPS is $0.601, ...

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Novavax raised its full-year adjusted revenue forecast on Wednesday, banking on higher sales tied to its vaccine supply ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the second quarter ended ...

Novavax beats Q2 expectations with $239 million in revenue, lifts 2025 guidance, and reports profit as costs decline and ...

Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 ...

Novavax (NVAX) stock gains as the company beats Q2 revenue estimates and raises its 2025 revenue outlook, buoyed by ...

Novavax shares shot higher after the biotechnology company's second-quarter profit and revenue beat analyst expectations. Shares were up 15% at $7.73 on Wednesday. The stock is up 33% over the past ...

Topline Shares for Novavax swelled by more than 130% Friday morning, after the biotech firm announced a $1.4 billion deal with Sanofi to commercialize its Covid vaccine and develop a new ...